Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Nicotine addiction and the neurobiological mechanisms explaining nicotine reinforcement, withdrawal, and relapse involve alpha4beta2 nicotinic acetylcholine receptors (nAChRs). This review updates readers on the preclinical and clinical pharmacology, as well as the therapeutic efficacy and safety of cytisine and varenicline, the two partial agonists of nAChRs for smoking cessation. Cytisine has been used for several decades; yet despite its surprising popularity in some parts of the world, it has been absent from almost all existing reviews of smoking cessation drugs. If safe and sufficiently efficacious, an obvious advantage would be its low cost, which could make cytisine an attractive treatment available to millions of smokers. Varenicline was recently introduced to the drug market and has been found to be more efficacious than existing treatments. Very encouraging results of early human trials and strong theoretical background for their use make the nAChRs partial agonists a promising alternative for currently available antismoking treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“Evidence from recent systematic reviews suggests that industry-funded trials, although conducted to a high standard, are more likely to have outcomes favorable to the product sponsor than studies with other sponsors [53,95] .”
ResultA controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“13 compared with placebo for ≥ 6 months abstinence [12-14] or the OR 1.”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 5×
“Moreover, a comparison of the results obtained in the independently conducted study with those from manufacturer-sponsored trials demonstrates that the frequency of insomnia in the former was higher than in the latter [57,79,80,83,86,88] .”
BackgroundResultInfluentialPicciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 3×
“Although a large number of neuronal subtypes have been identified, the presynaptic α 4 β 2 nAChRs play a crucial role in generating the discriminative stimulus properties of nicotine [20,24] .”
BackgroundOutcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 5×
“In animals treated concurrently with nicotine, cytisine inhibits the nicotine response by 36% [22] .”
BackgroundResultInfluentialDramatic decreases in brain reward function during nicotine withdrawal
Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998) · Nature · doi:10.1038/30001 · Cited by 674
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · cited 4×
“Moreover, a comparison of the results obtained in the independently conducted study with those from manufacturer-sponsored trials demonstrates that the frequency of insomnia in the former was higher than in the latter [57,79,80,83,86,88] .”
BackgroundResultInfluential
Cited by
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Placebo-controlled trial of cytisine for smoking cessation
West, R., Zatonski, W., Cedzynska, M., Lewandowska, D., Pazik, J., Aveyard, P., & Stapleton, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102035 · Cited by 234
Spiller, K., Xi, Z.-X., Li, X., Ashby, C. R., Callahan, P. M., Tehim, A., & Gardner, E. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.04.006 · Cited by 58
Metadata
- Authors
- Tutka, P.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2008-09-22
- Volume
- 17
- Issue
- 10
- Pages
- 1473-1485
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2171420658
- Cited by
- 32
- References
- 20
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. https://app.cochat.ai/papers/10.1517/13543784.17.10.1473
- The paper
- Tutka, P. (2008). Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.17.10.1473
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.